Taysha Gene Therapies, Inc. Share Price & Technical Analysis
TSHA · $5.47 (-3.87%)
Healthcare / Biotechnology
$5.47
-3.87%
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 d…
Price chart
Seasonality
Jun has 1 positive and 3 negative years (last 5 years shown)
-2% return in Jun, -17% avg return in past 3 year Jun month.
17% return in 2026, 155% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -18% | 0% | 2% | 42% | -8% | -2% | – | – | – | – | – | – | 17% |
| 25 | -17% | 7% | -12% | 36% | 35% | -15% | 17% | 7% | 14% | 56% | 9% | 20% | 157% |
| 24 | -12% | 113% | -9% | -14% | 42% | -37% | -8% | -4% | -9% | -15% | 88% | -48% | 85% |
| 23 | -30% | -23% | -20% | 0% | -12% | 0% | 0% | 357% | 0% | -28% | -22% | 0% | 221% |
| 22 | -34% | -26% | -4% | -44% | -31% | 42% | 11% | -20% | -41% | -15% | 22% | 5% | -135% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.62B
P/E ratio
—
52W high
$7.30
52W low
$2.25
Volume
5,53,993
Beta
1.23
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Taysha Gene Therapies, Inc. share price today?
- Taysha Gene Therapies, Inc. (TSHA) last traded around $5.47 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TSHA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TSHA. Download the app for real-time alerts.
- How can I analyze Taysha Gene Therapies, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.